{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:05:11Z","timestamp":1762340711113,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,9,9]],"date-time":"2015-09-09T00:00:00Z","timestamp":1441756800000},"content-version":"vor","delay-in-days":373,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000174","name":"Associazione Italiana contro le Leucemie-Linfomi e Mieloma (AIL)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000174","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.bbmt.2014.05.019","type":"journal-article","created":{"date-parts":[[2014,5,28]],"date-time":"2014-05-28T12:46:45Z","timestamp":1401281205000},"page":"1399-1406","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Mobilization-Driven Postconsolidation Therapy in Elderly Patients with Acute Myeloid Leukemia: Feasibility and Efficacy of Autologous Stem Cell Transplantation versus Low-Dose Gemtuzumab Ozogamicin"],"prefix":"10.1016","volume":"20","author":[{"given":"Debora","family":"Capelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Chiarucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Poloni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Saraceni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgia","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Trappolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Troiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Montanari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Scortechini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2749-7347","authenticated-orcid":false,"given":"Massimo","family":"Offidani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Rupoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Rita","family":"Scortechini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Gini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarlo","family":"Discepoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Leoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attilio","family":"Olivieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2014.05.019_bib1","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1182\/blood-2006-04-014324","article-title":"Cytogenetics and age are the major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from the AMLSG trial AML HD98-B","volume":"108","author":"Fr\u00f6hling","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.05.019_bib2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1182\/blood-2005-11-4354","article-title":"Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from cancer and leukemia group B 8461. Cancer and Leukemia Group B 8461","volume":"108","author":"Farag","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.05.019_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/asheducation.V2012.1.1.3797038","article-title":"Treatment of acute myeloid leukemia: are we making progress?","volume":"2012","author":"Burnett","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.bbmt.2014.05.019_bib4","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa0901409","article-title":"High-dose daunorubicin in older patients with acute myeloid leukemia","volume":"361","author":"L\u00f6wenberg","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2014.05.019_bib5","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1182\/blood-2010-03-276485","article-title":"Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.05.019_bib6","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1182\/blood.V88.8.2841.bloodjournal8882841","article-title":"A\u00a0randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study","volume":"88","author":"Weick","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.05.019_bib7","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1200\/JCO.2005.04.5013","article-title":"Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia","volume":"24","author":"B\u00fcchner","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.05.019_bib8","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3324\/haematol.10552","article-title":"Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC\u2013GIMEMA AML\u201313 study","volume":"92","author":"Thomas","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2014.05.019_bib9","first-page":"791","article-title":"Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol","volume":"89","author":"Oriol","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2014.05.019_bib10","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1080\/10428190600624730","article-title":"Feasibility of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia","volume":"47","author":"Ferrara","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2014.05.019_bib11","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.2165\/00003495-200565160-00014","article-title":"Gemtuzumab ozogamicin: a review of its use in acute myeloid leukaemia","volume":"65","author":"Fenton","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.bbmt.2014.05.019_bib12","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","article-title":"Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 Trial","volume":"29","author":"Burnett","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.05.019_bib13","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2014.05.019_bib14","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2009-10-246470","article-title":"Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study","volume":"115","author":"L\u00f6wenberg","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.05.019_bib15","doi-asserted-by":"crossref","unstructured":"Burnett AK, Russell NH, Hills RK, et\u00a0al. The addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukaemia. J Clin Oncol e-pub ahead of print 30 July 2012; http:\/\/dx.doi.org\/10.1200\/JCO.2012.42.2964.","DOI":"10.1200\/JCO.2012.42.2964"},{"key":"10.1016\/j.bbmt.2014.05.019_bib16","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/j.1365-2141.2008.07247.x","article-title":"Gemtuzumab ozogamicin as maintenance therapy after autologous stem cell transplantation in elderly patients with acute myeloid leukaemia","volume":"142","author":"Cascavilla","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2014.05.019_bib17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1365-2141.2010.08168.x","article-title":"Low-dose gemtuzumab-ozogamicin as post-consolidation therapy in elderly patients with acute myeloid leukaemia: a pilot study","volume":"150","author":"Poloni","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2014.05.019_bib18","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/sj.bmt.1703034","article-title":"Very low toxicity and good quality of life in 48 elderly patients autotransplanted for hematological malignancies: a single center experience","volume":"27","author":"Olivieri","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.05.019_bib19","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1200\/JCO.1990.8.5.813","article-title":"Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia","volume":"8","author":"Cheson","year":"1990","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.05.019_bib20","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"European LeukemiaNet Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"D\u00f6hner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.05.019_bib21","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.05.019_bib22","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/0145-2126(94)00162-4","article-title":"Cytogenetic correlation with disease status and treatment outcome in advanced stage leukemia post bone marrow transplantation: a Southwest Oncology Group study (SWOG-8612)","volume":"19","author":"Slovak","year":"1995","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2014.05.019_bib23","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1200\/JCO.2010.32.8500","article-title":"Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system","volume":"29","author":"R\u00f6llig","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.05.019_bib24","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.3324\/haematol.13309","article-title":"Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia","volume":"93","author":"Malfuson","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2014.05.019_bib25","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1182\/blood-2007-06-096966","article-title":"Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences","volume":"110","author":"Sorror","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.05.019_bib26","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.bbmt.2014.05.019_bib27","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/sj.leu.2402782","article-title":"The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial","volume":"17","author":"Keating","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2014.05.019_bib28","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.exphem.2007.03.013","article-title":"A\u00a0new intensive induction schedule, including high-dose idarubicin, high-dose aracytin and amifostine, in older AML patients: feasibility and long-term results in 42 patients","volume":"35","author":"Olivieri","year":"2007","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2014.05.019_bib29","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1182\/blood.V87.5.1710.1710","article-title":"A\u00a0randomized study of high-dose cytarabine in induction in acute myeloid leukemia","volume":"87","author":"Bishop","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.05.019_bib30","first-page":"4173","article-title":"Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype","volume":"58","author":"Bloomfield","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2014.05.019_bib31","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/sj.leu.2404122","article-title":"Intensive consolidation versus oral maintenance therapy in patients 61 years or older with acute myeloid leukemia in first remission: results of second randomization of the AML HD98-B treatment trial","volume":"20","author":"Schlenk","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2014.05.019_bib32","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.1182\/blood-2007-02-069666","article-title":"Post-remission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial","volume":"109","author":"Gardin","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.05.019_bib33","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/blood-2002-12-3714","article-title":"Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC\/GIMEMA AML-10 trial","volume":"102","author":"Suciu","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.05.019_bib34","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(97)09214-3","article-title":"Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial","volume":"351","author":"Burnett","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2014.05.019_bib35","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.transci.2009.05.011","article-title":"Management of poor peripheral blood stem cell mobilization: incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions","volume":"41","author":"Perseghin","year":"2009","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.bbmt.2014.05.019_bib36","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1182\/blood-2009-11-252197","article-title":"Higher incidence of relapse in patients with acute myelocytic leukemia infused with higher doses of CD34+ cells from leukapheresis products autografted during the first remission","volume":"116","author":"Gorin","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.05.019_bib37","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/jnci\/djh003","article-title":"Consolidation therapy with autologous bone marrow transplantation in adults with acute myeloid leukemia: a meta-analysis","volume":"96","author":"Nathan","year":"2004","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.bbmt.2014.05.019_bib38","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1080\/10428190500513595","article-title":"Consolidation therapy for adult acute myeloid leukemia: a systematic analysis according to evidence based medicine","volume":"47","author":"Visani","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2014.05.019_bib39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.bbmt.2008.11.016","article-title":"Is there a role for autotransplants in AML in first remission?","volume":"15","author":"Seshadri","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.05.019_bib40","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.2008.20.1400","article-title":"Higher incidence of relapse with peripheral blood rather than marrow as a source of stem cells in adults with acute myelocytic leukemia autographed during the first remission","volume":"27","author":"Gorin","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.05.019_bib41","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1182\/blood-2013-03-490482","article-title":"Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug","volume":"121","author":"Rowe","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.05.019_bib42","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1080\/10428190600572673","article-title":"Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia","volume":"47","author":"Greenwood","year":"2006","journal-title":"Leuk Lymphoma"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879114003176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879114003176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:48:31Z","timestamp":1761058111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879114003176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S1083879114003176"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2014.05.019","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mobilization-Driven Postconsolidation Therapy in Elderly Patients with Acute Myeloid Leukemia: Feasibility and Efficacy of Autologous Stem Cell Transplantation versus Low-Dose Gemtuzumab Ozogamicin","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2014.05.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}